Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 9NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 17Burkitt Lymphoma 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Rectal Neoplasms 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lung Neoplasms 2Leukemia, Biphenotypic, Acute 2Immunoglobulin Light-chain Amyloidosis 2Down Syndrome 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1Rhabdoid Tumor 1Recurrence 1Prolactinoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmacytoma 1Pituitary Neoplasms 1Oropharyngeal Neoplasms 1Optic Nerve Glioma 1Oligodendroglioma 1Neoplasms, Plasma Cell 1Mesothelioma 1Medulloblastoma 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1

Interventions

Melphalan 2Dexamethasone 1Calcium Dobesilate 1Bortezomib 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Amyloidosis × Calcium Dobesilate × Clear all
NCT01078454 2022-02-01

Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis

National Cancer Institute (NCI)

Phase 3 Completed
11 enrolled 6 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡